The PROTECT Trial for IgAN Patients
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Breve descripción
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
Médico del ensayo/Coordinador del estudio
Kanchana Karunaratne
Correo electrónico Número de teléfono (818) 992-8505Nombre del sitio
California Medical Research Associates inc.
Roscoe Boulevard, Northridge, CA, USA
Nombre del patrocinador
Retrophin, Inc.
Nombre del fármaco del estudio
Sparsentan
Matrícula estimada
280
Fecha estimada de finalización
April 2023
The PROTECT Trial for IgAN Patients
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Breve descripción
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
El ensayo es para personas con
IgA Nephropathy (IgAN)
Objetivo del estudio
To evaluate the potential benefit of Sparsentan on kidney function by analyzing change in proteinuria (protein in urine) and estimated glomerular filtration rate (eGFR) as compared to current standard treatment.
Qué implica para el paciente?
Patients will take a daily dose of the study medication, and will be involved with the trial for about 2 years.
Sobre el medicamento o la intervención
Sparsentan is a tablet taken orally.